Physician profile
Suying Wu
NPI 1669477816
$12,053.60
in general payments reported to CMS, 2019-2025
61 companies · $2,448 in 2025
The $2,448 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,604 · 2020: $349 · 2021: $647 · 2022: $1,613 · 2023: $2,304 · 2024: $3,088 · 2025: $2,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,828 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,828.31 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $866.27 | 2022-2025 | Zeposia |
| Catalyst Pharmaceuticals, INC. | $808.52 | 2023-2025 | Fycompa |
| Jazz Pharmaceuticals INC. | $791.29 | 2019-2025 | |
| Ucb, INC. | $671.14 | 2019-2025 | Rystiggo, Briviact, Fintepla |
| Abbvie INC. | $660.53 | 2021-2025 | Botox, Ubrelvy, Duopa |
| Novartis Pharmaceuticals Corporation | $584.81 | 2019-2025 | |
| Argenx US, INC. | $496.69 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Biogen, INC. | $454.21 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Emd Serono, INC. | $409.07 | 2019-2025 | Mavenclad, Mavenclad |
| Teva Pharmaceuticals USA, INC. | $334.42 | 2019-2024 | Ajovy, Austedo Xr, Austedo |
| Genzyme Corporation | $326.20 | 2019-2023 | |
| Eisai INC. | $324.91 | 2019-2025 | |
| Genentech USA, INC. | $291.36 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Banner Life Sciences, LLC | $284.01 | 2023-2024 | |
| Allergan, INC. | $272.43 | 2019-2022 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $269.07 | 2022-2024 | |
| Amgen INC. | $266.85 | 2019-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $260.55 | 2020-2025 | Ingrezza, Ongentys |
| Axsome Therapeutics, INC. | $244.64 | 2023-2025 | Sunosi |
| Lundbeck LLC | $238.74 | 2021-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $228.58 | 2019-2025 | Ultomiris, Soliris |
| Acadia Pharmaceuticals INC | $226.87 | 2020-2025 | Nuplazid |
| Pfizer INC. | $224.86 | 2019-2025 | |
| Livanova USA, INC. | $215.23 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $170.82 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Sunovion Pharmaceuticals INC. | $158.70 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $139.22 | 2025 | Ponvory |
| Adamas Pharmaceuticals, INC. | $130.52 | 2019-2021 | |
| Piramal Critical Care | $130.46 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $117.13 | 2021-2025 | Acthar |
| Tg Therapeutics, INC. | $100.07 | 2023-2025 | |
| Acorda Therapeutics, INC | $93.45 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $90.57 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $89.58 | 2023-2025 | Dysport |
| Horizon Therapeutics Plc | $88.37 | 2022-2023 | Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $80.81 | 2022 | |
| Alnylam Pharmaceuticals INC. | $75.75 | 2023 | Onpattro |
| Sumitomo Pharma America, INC. | $74.53 | 2023-2025 | Aptiom, Gemtesa |
| Amneal Pharmaceuticals LLC | $65.39 | 2023-2024 | Crexont, Lioresal (Baclofen), Rytary |
| Merck Sharp & Dohme LLC | $58.22 | 2022-2024 | Belsomra, Steglatro, Gardasil |
| Tanabe Pharma America, INC. | $54.76 | 2019-2025 | Radicava |
| Janssen Pharmaceuticals, INC | $51.87 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $48.73 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $48.52 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $47.68 | 2021 | |
| Nevro Corp. | $43.82 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $38.29 | 2023 | Relyvrio |
| Grifols USA, LLC | $38.00 | 2022-2024 | Gamunex-C |
| Boston Scientific Corporation | $36.00 | 2024 | Watchman Flx |
| Saol Therapeutics INC. | $33.48 | 2019 | |
| Mdd US Operations, LLC | $29.07 | 2020-2022 | |
| Cycle Pharmaceuticals INC | $24.19 | 2025 | Bafiertam |
| Kyowa Kirin, INC. | $20.48 | 2020 | |
| Novo Nordisk INC | $18.47 | 2023 | Rybelsus, Ozempic |
| Avadel Cns Pharmaceuticals, LLC | $17.53 | 2024 | Lumryz |
| Octapharma USA, INC. | $15.63 | 2023 | Panzyga |
| Abbott Laboratories | $15.20 | 2023 | Infinity |
| Chiesi USA, INC. | $14.69 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.57 | 2024 | Nuedexta |
| Merz Pharmaceuticals, LLC | $14.06 | 2025 | Xeomin |
| Zyla Life Sciences, INC. | $13.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suying Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.